|Bid||19.07 x 1400|
|Ask||19.09 x 800|
|Day's Range||18.84 - 19.20|
|52 Week Range||11.98 - 21.86|
|Beta (5Y Monthly)||1.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 10, 2021 - Feb 15, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.45|
Richard Pops has been the CEO of Alkermes plc (NASDAQ:ALKS) since 2011, and this article will examine the executive's...
Pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and Bristol Myers (BMY) among others provide updates.
Alkermes (ALKS) gets a CRL by the FDA for ALKS 3831 for the treatment of adults with schizophrenia and bipolar I disorder.